LISTING OF CLAIMS

The following listing of claims replaces all prior versions and listings of the claims in this application.

Listing of Claims

Claims 1-26. (Canceled)

27. (Currently Amended) An endoprosthesis for soft tissue augmentation [[consisting essentially of a polymer hydrogel]];

said [[polymer hydrogel]] endoprosthesis being injectable into soft tissue as a polymer hydrogel and having a complex viscosity of about 2 to 100 Pas;

said polymer hydrogel comprising

less than 50 ppm of acrylamide [[and]] or methylene-bis-acrylamide,

at least 95% by weight pyrogen-free water or a saline solution, and

at least 0.5% by weight polyacrylamide and less than 3.5% by weight polyacrylamide, based on the total weight of the polymer hydrogel[[,]] ;

wherein said [[endoprosthesis has a complex viscosity of about 2 to 100Pas]] polyacrylamide consists essentially of a cross-linked polymerized acrylamide, wherein the cross-linking consists essentially of the use of N,'N'-methylene bis-acrylamide as a cross-linker;

and wherein said endoprosthesis consists essentially of said polymer hydrogel [[the endoprosthesis is injectable into soft tissue]].

28. (Canceled)

29. (Previously presented) The endoprosthesis according to claim 27, wherein the polymer hydrogel comprises about 1.9 to 2.9% by weight polyacrylamide, based on the total weight of the polymer hydrogel.

30. (Canceled)

31. (Previously presented) The endoprosthesis according to claim 27, wherein the polymer hydrogel further comprises cells for cellular engraftment to the surrounding tissue.

32. (Previously presented) The endoprosthesis according to claim 31, wherein the cells are stem cells.

33. (Previously presented) The endoprosthesis according to claim 27, wherein the polymer hydrogel comprises at least 1.5% and less than 3.5% by weight polyacrylamide, based on the total weight of the polymer hydrogel.

34. (Canceled)

35. (Previously presented) The endoprosthesis according to claim 27 for at least one of cosmetic surgery of the face, reconstructive surgery of the face, body contouring, augmentation of the lips or reconstructive surgery of the lips.

36. (Previously presented) The endoprosthesis according to claim 35 for cosmetic or reconstructive surgery of the face having a complex viscosity of about 2 to 20 Pas.

37. (Previously presented) The endoprosthesis according to claim 35 for body contouring having a complex viscosity of about 5 to 50 Pas.

38. (Previously presented) The endoprosthesis according to claim 35 for augmentation or reconstructive surgery of the lips having a complex viscosity of about 2 to 10 Pas.

39. (Previously presented) The endoprosthesis according to claim 27 for use in correction of facial contour deformities due to at least one of aging, acne, trauma, surgery, infection or congenital deformities.

40. (Previously presented) The endoprosthesis according to claim 39 wherein the correction of facial contour deformities is selected from the group consisting of at least one of a correction of the cheekbones, a correction of nasolabial folds, a correction of glabellar frowns, a correction

of depressed contours of the mouth, a correction to the chin, a correction to size of the lips, a correction to shape of the lips, and a correction to other soft tissue deficiencies of the face.

Claims 41-43. (Canceled)

44. (Previously presented) The endoprosthesis of claim 27 wherein the polymer hydrogel comprises less than 40 ppm monomeric units.

Claims 45-47. (Canceled)

48. (Previously presented) The endoprosthesis of claim 27 wherein the polymer hydrogel comprises less than 20 ppm monomeric units.

49. (Previously presented) The endoprosthesis according to claim 27, wherein said polyacrylamide is made by a method comprising washing with pyrogen-free water or a saline solution after the acrylamide is polymerized.

50. (Previously presented) The endoprosthesis according to claim 27, wherein said endoprosthesis is stored in a syringe.

51. (Previously presented) The endoprosthesis according to claim 50, wherein said syringe has a volume selected from the group consisting of 0.5 mL, 0.7 mL, 1.0 ml, 1.5 mL, 2.0 mL, 2.5 mL, 5.0 mL, 7.5 mL, 10 mL, 12.5 mL, 15 mL, 20 mL, and 25 mL.

52. (Currently Amended) A method for soft tissue augmentation comprising administering to an area in need thereof an endoprosthesis; [[consisting essentially of a polymer hydrogel,]] ;

said endoprosthesis being injected into soft tissue as a polymer hydrogel and having a complex viscosity of about 2 to 100 Pas;;

said polymer hydrogel comprising

less than 50 ppm of acrylamide [[or]] and methylene-bis-acrylamide,

at least 95% by weight pyrogen-free water or a saline solution, and

at least 0.5% by weight polyacrylamide and less than 3.5% by weight polyacrylamide, based on the total weight of the polymer hydrogel;

wherein said polyacrylamide consists essentially of a cross-linked polymerized acrylamide, wherein the cross-linking consists essentially of the use of N',N' methylene-bis-acrylamide as a cross-linker,

said endoprosthesis consisting essentially of said polymer hydrogel[[and wherein the endoprosthesis is injectable into soft tissue]].

53. (Canceled)

54. (Previously presented) The method according to claim 52, wherein the polymer hydrogel comprises about 1.9 to 2.9% by weight polyacrylamide, based on the total weight of the polymer hydrogel.

55. (Canceled)

56. (Previously presented) The method according to claim 52, wherein the polymer hydrogel further comprises cells for cellular engraftment to the surrounding tissue.

57. (Previously presented) The method according to claim 56, wherein the cells are stem cells.

58. (Previously presented) The method according to claim 52, wherein the polymer hydrogel comprises at least 1.5% and less than 3.5% by weight polyacrylamide, based on the total weight of the polymer hydrogel.

59. (Previously presented) The method according to claim 52, wherein the soft tissue augmentation is selected from the group consisting of at least one of cosmetic surgery of the face, reconstructive surgery of the face, body contouring, augmentation of the lips and reconstructive surgery of the lips.

60. (Previously presented) The method according to claim 59, wherein the soft tissue augmentation is cosmetic or reconstructive surgery of the face and wherein the endoprosthesis has a complex viscosity of about 2 to 20 Pas.

61. (Previously presented) The method according to claim 59, wherein the soft tissue augmentation is body contouring and the endoprosthesis has a complex viscosity of about 5 to 50 Pas.

62. (Previously presented) The method according to claim 59, wherein the soft tissue augmentation is augmentation or reconstructive surgery of the lips and the endoprosthesis has a complex viscosity of about 2 to 10 Pas.

63. (Previously presented) The method according to claim 52, wherein the soft tissue augmentation is correction of facial contour deformities due to at least one of aging, acne, trauma, surgery, infection or congenital deformities.

64. (Previously presented) The method according to claim 63, wherein the correction of facial contour deformities is selected from the group consisting of at least one of a correction of the cheekbones, a correction of nasolabial folds, a correction of glabellar frowns, a correction of depressed contours of the mouth, a correction to the chin, a correction to size of the lips, a correction to shape of the lips, and a correction to other soft tissue deficiencies of the face.

Claims 65-66. (Canceled)

67. (Previously presented) The method according to claim 52, wherein the polymer hydrogel comprises less than 40 ppm monomeric units.

Claims 68.-70. (Canceled)

71. (Previously presented) The method according to claim 52, wherein the polymer hydrogel comprises less than 20 ppm monomeric units.

72. (Previously presented) The method according to claim 52, wherein said polyacrylamide is made by a method comprising washing with pyrogen-free water or a saline solution after the acrylamide is polymerized.

73. (Previously presented) The method according to claim 52, wherein said endoprosthesis is stored in a syringe.

74. (Previously presented) The method according to claim 73, wherein said syringe has a volume selected from the group consisting of 0.5 mL, 0.7 mL, 1.0 ml, 1.5 mL, 2.0 mL, 2.5 mL, 5.0 mL, 7.5 mL, 10 mL, 12.5 mL, 15 mL, 20 mL, and 25 mL.

75. (Previously presented) The endoprosthesis of claim 27, wherein the polymer hydrogel consists essentially of the formula $(C_3H_5NO)_x(C_7H_{10}N_2O_2)_y$, wherein x and y are such that to be in a ratio of 150 – 1000 to 1.

76. (Previously presented) The method according to claim 52, wherein the polymer hydrogel consists essentially of the formula $(C_3H_5NO)_x(C_7H_{10}N_2O_2)_y$, wherein x and y are such that to be in a ratio of 150 – 1000 to 1.